Development and Validation of Novel Models Including Tumor Micronecrosis for Predicting the Postoperative Survival of Patients with Hepatocellular Carcinoma

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Ercolani G, Grazi GL, Ravaioli M, et al. Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg. 2003;237(4):536–543. doi:10.1097/01.SLA.0000059988.22416.F2
   PubMed Web of Science ®Google Scholar
• Edge SB, Compton CC. The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–1474. doi:10.1245/s10434-010-0985-4
   PubMed Web of Science ®Google Scholar
• Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol. 2003;38(3):207–215. doi:10.1007/s005350300038
   PubMed Web of Science ®Google Scholar
• Leung TW, Tang AM, Zee B, et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer. 2002;94(6):1760–1769. doi:10.1002/cncr.10384
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–693. doi:10.1016/j.jhep.2021.11.018
   PubMed Web of Science ®Google Scholar
• Tateishi R, Yoshida H, Shiina S, et al. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut. 2005;54(3):419–425. doi:10.1136/gut.2003.035055
   PubMed Web of Science ®Google Scholar
• Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology. 2014;146(7):1691–1700 e1693. doi:10.1053/j.gastro.2014.02.032
   PubMed Web of Science ®Google Scholar
• Shindoh J, Andreou A, Aloia TA, et al. Microvascular invasion does not predict long-term survival in hepatocellular carcinoma up to 2 cm: reappraisal of the staging system for solitary tumors. Ann Surg Oncol. 2013;20(4):1223–1229. doi:10.1245/s10434-012-2739-y
   PubMed Web of Science ®Google Scholar
• Karsch-Bluman A, Benny O. Necrosis in the tumor microenvironment and its role in cancer recurrence. Adv Exp Med Biol. 2020;1225:89–98.
   PubMed Web of Science ®Google Scholar
• Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007;26(2):225–239. doi:10.1007/s10555-007-9055-1
   PubMed Web of Science ®Google Scholar
• Wang Y, Ge H, Hu M, et al. Histological tumor micronecrosis in resected specimens after R0 hepatectomy for hepatocellular carcinomas is a factor in determining adjuvant TACE: a retrospective propensity score-matched study. Int J Surg. 2022;105:106852. doi:10.1016/j.ijsu.2022.106852
   PubMed Web of Science ®Google Scholar
• Kang L, Chen W, Petrick NA, Gallas BD. Comparing two correlated C indices with right-censored survival outcome: a one-shot nonparametric approach. Stat Med. 2015;34(4):685–703. doi:10.1002/sim.6370
   PubMed Web of Science ®Google Scholar
• Royston P, Altman DG. External validation of a Cox prognostic model: principles and methods. BMC Med Res Methodol. 2013;13:33. doi:10.1186/1471-2288-13-33
   PubMed Web of Science ®Google Scholar
• Wang K, Liu G, Li J, et al. Early intrahepatic recurrence of hepatocellular carcinoma after hepatectomy treated with re-hepatectomy, ablation or chemoembolization: a prospective cohort study. Eur J Surg Oncol. 2015;41(2):236–242. doi:10.1016/j.ejso.2014.11.002
   PubMed Web of Science ®Google Scholar
• Yamamoto J, Okada S, Shimada K, et al. Treatment strategy for small hepatocellular carcinoma: comparison of long-term results after percutaneous ethanol injection therapy and surgical resection. Hepatology. 2001;34(4 Pt 1):707–713. doi:10.1053/jhep.2001.27950
   PubMed Web of Science ®Google Scholar
• van Malenstein H, van Pelt J, Verslype C. Molecular classification of hepatocellular carcinoma anno 2011. Eur J Cancer. 2011;47(12):1789–1797. doi:10.1016/j.ejca.2011.04.027
   PubMed Web of Science ®Google Scholar
• Villanueva A, Hoshida Y, Toffanin S, et al. New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res. 2010;16(19):4688–4694. doi:10.1158/1078-0432.CCR-09-1811
   PubMed Web of Science ®Google Scholar
• Chatzopoulos K, Kotoula V, Koliou GA, et al. Genotype-phenotype associations in colorectal adenocarcinomas and their matched metastases. Hum Pathol. 2021;107:104–116. doi:10.1016/j.humpath.2020.10.009
   PubMed Web of Science ®Google Scholar
• Hiraoka N, Ino Y, Sekine S, et al. Tumour necrosis is a postoperative prognostic marker for pancreatic cancer patients with a high interobserver reproducibility in histological evaluation. Br J Cancer. 2010;103(7):1057–1065. doi:10.1038/sj.bjc.6605854
   PubMed Web of Science ®Google Scholar
• Ye Q, Zhang Q, Tian Y, et al. Method of tumor pathological micronecrosis quantification via deep learning from label fuzzy proportions. IEEE J Biomed Health Inform. 2021;25(9):3288–3299. doi:10.1109/JBHI.2021.3071276
   PubMed Web of Science ®Google Scholar
• Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv238–iv255. doi:10.1093/annonc/mdy308
   PubMed Web of Science ®Google Scholar
• Zhao F. Surrogate end points and their validation in oncology clinical trials. J Clin Oncol. 2016;34(13):1436–1437. doi:10.1200/JCO.2016.66.4581
   PubMed Web of Science ®Google Scholar
• Kudo M. Newly developed modified ALBI grade shows better prognostic and predictive value for hepatocellular carcinoma. Liver Cancer. 2022;11(1):1–8. doi:10.1159/000521374
   PubMedGoogle Scholar
• Pinato DJ, Sharma R, Allara E, et al. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. J Hepatol. 2017;66(2):338–346. doi:10.1016/j.jhep.2016.09.008
   PubMed Web of Science ®Google Scholar
• Mao M, Wang X, Song Y, et al. Novel prognostic scores based on plasma prothrombin time and fibrinogen levels in patients with AFP-negative hepatocellular carcinoma. Cancer Control. 2020;27(1):1073274820915520. doi:10.1177/1073274820915520
   Web of Science ®Google Scholar
• Takaya H, Namisaki T, Takeda S, et al. The combination of albumin-bilirubin score and prothrombin time is a useful tool for predicting liver dysfunction after transcatheter arterial chemoembolization in Child-Pugh class A patients with hepatocellular carcinoma within up-to-seven criteria. J Clin Med. 2021;10(21):4838. doi:10.3390/jcm10214838
   PubMed Web of Science ®Google Scholar
• Wang XP, Mao MJ, He ZL, et al. A retrospective discussion of the prognostic value of combining prothrombin time(PT) and fibrinogen(Fbg) in patients with Hepatocellular carcinoma. J Cancer. 2017;8(11):2079–2087. doi:10.7150/jca.19181
   PubMed Web of Science ®Google Scholar
• Su K, Gu T, Xu K, et al. Gamma knife radiosurgery versus transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score matching study. Hepatol Int. 2022;16(4):858–867. doi:10.1007/s12072-022-10339-2
   PubMed Web of Science ®Google Scholar
• Su K, Guo L, Ma W, et al. PD-1 inhibitors plus anti-angiogenic therapy with or without intensity-modulated radiotherapy for advanced hepatocellular carcinoma: a propensity score matching study. Front Immunol. 2022;13:972503. doi:10.3389/fimmu.2022.972503
   PubMed Web of Science ®Google Scholar
• Su K, Guo L, He K, et al. PD-L1 expression on circulating tumor cells can be a predictive biomarker to PD-1 inhibitors combined with radiotherapy and antiangiogenic therapy in advanced hepatocellular carcinoma. Front Oncol. 2022;12:873830. doi:10.3389/fonc.2022.873830
   PubMed Web of Science ®Google Scholar
• Su K, Huang W, Li X, et al. Evaluation of lactate dehydrogenase and alkaline phosphatase as predictive biomarkers in the prognosis of hepatocellular carcinoma and development of a new nomogram. J Hepatocell Carcinoma. 2023;10:69–79. doi:10.2147/JHC.S398632
   PubMed Web of Science ®Google Scholar
• Su K, Liu Y, Wang P, et al. Heat-shock protein 90α is a potential prognostic and predictive biomarker in hepatocellular carcinoma: a large-scale and multicenter study. Hepatol Int. 2022;16(5):1208–1219. doi:10.1007/s12072-022-10391-y
   PubMed Web of Science ®Google Scholar